TWST logo

Twist Bioscience Corporation Stock Price

NasdaqGS:TWST Community·US$1.9b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 29 Fair Values set on narratives written by author

TWST Share Price Performance

US$31.19
-10.46 (-25.11%)
37.6% undervalued intrinsic discount
US$50.00
Fair Value
US$31.19
-10.46 (-25.11%)
49.7% undervalued intrinsic discount
US$62.00
Fair Value
Price US$31.19
AnalystHighTarget US$62.00
AnalystConsensusTarget US$40.00
AnalystLowTarget US$25.00

TWST Community Narratives

AnalystHighTarget·
Fair Value US$50 34.4% undervalued intrinsic discount

Automated DNA Synthesis And AI Will Fuel Secular Growth

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AnalystConsensusTarget·
Fair Value US$40 18.0% undervalued intrinsic discount

SynBio And NGS Demand Will Broaden Global Market Reach

0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
AnalystLowTarget·
Fair Value US$25 31.2% overvalued intrinsic discount

DNA Synthesis Commoditization And Trade Tensions Will Erode Margins

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative

Recent TWST News & Updates

Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 31%

Oct 09
Twist Bioscience Corporation (NASDAQ:TWST) Held Back By Insufficient Growth Even After Shares Climb 31%

Twist Bioscience Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Aug 07
Twist Bioscience Corporation Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year

Little Excitement Around Twist Bioscience Corporation's (NASDAQ:TWST) Revenues As Shares Take 28% Pounding

Aug 06
Little Excitement Around Twist Bioscience Corporation's (NASDAQ:TWST) Revenues As Shares Take 28% Pounding

We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth

Jul 28
We Think Twist Bioscience (NASDAQ:TWST) Can Easily Afford To Drive Business Growth

Twist Bioscience Corporation Key Details

US$362.3m

Revenue

US$183.9m

Cost of Revenue

US$178.4m

Gross Profit

US$263.6m

Other Expenses

-US$85.2m

Earnings

Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
n/a
Earnings per share (EPS)
-1.41
Gross Margin
49.24%
Net Profit Margin
-23.51%
Debt/Equity Ratio
3.1%

Twist Bioscience Corporation Competitors

 
 
 
 
 
 
 
 
 
 
 
 

Snowflake Analysis

Excellent balance sheet and fair value.

2 Risks
2 Rewards

About TWST

Founded
2013
Employees
923
CEO
Emily Leproust
WebsiteView website
www.twistbioscience.com

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Market Insight

Q4 2025 is off to a flying start with record highs being printed left, right, and center. US and Japanese stocks made fresh new highs, while the gold price powered through $4,000 for the first time, and Bitcoin crossed the $126k level. Is this all a case of USD weakness, irrational exuberance, or solid fundamentals? This week, we are reviewing Q3 market performance, Q2 earnings season, and the outlook heading into the end of 2025…
Continue reading

U.S. Market Performance

  • 7 Days: 0.3%
  • 3 Months: 8.5%
  • 1 Year: 17.3%
  • Year to Date: 15.0%
The market has stayed flat over the 7 days. More promisingly, the market is up 17% over the past year. Looking forward, earnings are forecast to grow by 15% annually. Market details ›